Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Total Non-Current Liabilities (2016 - 2025)

Sanara MedTech (SMTI) has disclosed Total Non-Current Liabilities for 15 consecutive years, with $47.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities rose 36.94% year-over-year to $47.6 million, compared with a TTM value of $47.6 million through Sep 2025, up 36.94%, and an annual FY2024 reading of $33.9 million, up 118.43% over the prior year.
  • Total Non-Current Liabilities was $47.6 million for Q3 2025 at Sanara MedTech, down from $48.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $48.5 million in Q2 2025 and bottomed at $187040.0 in Q1 2022.
  • Average Total Non-Current Liabilities over 5 years is $16.6 million, with a median of $7.9 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities tumbled 65.13% in 2021, then surged 4116.63% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $222151.0 in 2021, then soared by 2830.03% to $6.5 million in 2022, then skyrocketed by 138.36% to $15.5 million in 2023, then skyrocketed by 118.43% to $33.9 million in 2024, then surged by 40.43% to $47.6 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for SMTI at $47.6 million in Q3 2025, $48.5 million in Q2 2025, and $46.4 million in Q1 2025.